Literature DB >> 30999038

Reconciling the controversial data on the effects of C60 fullerene at the organismal and molecular levels using as a model Drosophila melanogaster.

Y Yasinskyi1, Protsenko O2, Maistrenko O3, Rybalchenko V2, Yu Prylutskyy2, E Tauscher4, U Ritter4, I Kozeretska2.   

Abstract

Fullerenes have attracted attention since their discovery as structural units of complex carbon nanostructures capable of transporting drugs and macromolecules. As such artificial nanomaterials are applied in biology and medicine, they are routinely scrutinized for their effects on living organisms. The results of such studies range from direct destabilizing effects on DNA molecules to amelioration of the toxic effects of known genotoxic agents. We tested the effect of buckminsterfullerene (C60) on Drosophila melanogaster at DNA, tissue and organism levels. The water-soluble pristine C60 fullerene at the concentration of 20 μg/ml and 40 μg/ml leads to the activation of the mus209 gene in D. melanogaster larvae salivary glands, which can indicate higher levels of DNA damage. However, the absence of effects at the cell and organismal level could be explained by the activation of repair systems or by active elimination of damaged cells.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  C(60)fullerene; Drosophila melanogaster; Genotoxicity

Mesh:

Substances:

Year:  2019        PMID: 30999038     DOI: 10.1016/j.toxlet.2019.03.006

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  2 in total

1.  Drosophila as a Suitable In Vivo Model in the Safety Assessment of Nanomaterials.

Authors:  Eşref Demir; Fatma Turna Demir; Ricard Marcos
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  C60 Fullerene as an Effective Nanoplatform of Alkaloid Berberine Delivery into Leukemic Cells.

Authors:  Anna Grebinyk; Svitlana Prylutska; Anatoliy Buchelnikov; Nina Tverdokhleb; Sergii Grebinyk; Maxim Evstigneev; Olga Matyshevska; Vsevolod Cherepanov; Yuriy Prylutskyy; Valeriy Yashchuk; Anton Naumovets; Uwe Ritter; Thomas Dandekar; Marcus Frohme
Journal:  Pharmaceutics       Date:  2019-11-08       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.